AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AVBP · NASDAQ · Biotechnology

ArriVent BioPharma (AVBP)

Develops licensed oncology assets led by firmonertinib and antibody-drug conjugates.

$30.32

After hours−0.03 (−0.10%)

At close$30.35(+2.05%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
	17	23	21	26	24	24	67	34	38	39	46	53
Research & development	14	20	17	22	20	20	61	28	32	32	38	42
	2	3	4	4	4	4	5	6	6	7	8	10
General & administrative	2	3	4	4	4	4	5	6	6	7	8	10
Operating income	−17	−23	−21	−26	−24	−24	−67	−34	−38	−39	−46	−53
	2	2	3	4	4	3	2	2	3	3	3	3
Interest income	2	2	3	4	4	3	2	2	3	3	3	3
Other non-operating income	−2	−2	−3	−4	−4	−3	−2	−2	−3	−3	−3	−3
Income before tax	−14	−21	−17	−22	−21	−21	−64	−31	−35	−36	−43	−50
Net income from continuing operations	−14	−21	−17	−22	−21	−21	−64	−31	−35	−36	−43	−50
Net income	−14	−21	−17	−22	−21	−21	−64	−31	−35	−36	−43	−50
EPS, basic	−$0.43	−$0.63	−$0.52	−$0.65	−$0.61	−$0.61	−$1.90	−$0.90	−$0.83	−$0.84	−$0.96	−$1.05
EPS, diluted	−$0.43	−$0.63	−$0.52	−$0.65	−$0.61	−$0.61	−$1.90	−$0.90	−$0.83	−$0.84	−$0.96	−$1.05
Weighted average shares, basic	33	33	33	34	34	34	34	35	42	38	45	48
Weighted average shares, diluted	33	33	33	34	34	34	34	35	42	38	45	48
EBITDA	−14	−21	−17	−22	−21	−21	−64	−31	−35	−36	−43	−50
EBIT	−14	−21	−17	−22	−21	−21	−64	−31	−35	−36	−43	−50